Williamstown, MA -- (SBWIRE) -- 04/18/2012 -- In 2011, the Branded PharmaVitae Universe achieved sales of $558bn having experienced a compound annual growth rate (CAGR) of 9.3% between 2003 and 2010, and a net sales growth of $253bn. However, during 2011-16 sales are forecast to grow by a CAGR of only 1.0%, with no growth forecast in 2012, and branded prescription sales rising by just $29bn by 2016.

Report Scope:

- Analyzes the forecast sales of the Branded PharmaVitae Universe according to molecule type
- Analyzes the forecast sales of the Branded PharmaVitae Universe according to therapy area
- Analyzes the forecast sales of the Branded PharmaVitae Universe according to geographical market
- Analyzes the forecast sales of the Branded PharmaVitae Universe according to formulation type

View Full Report Details and Table of Contents

Report Highlights

By 2016 the small molecule market will contract by $5bn compared to 2011 sales as a direct consequence of the patent cliff and resultant generic erosion of branded sales. In preparation for this, the pharmaceutical industry has for some years been shifting its strategy to focus increasingly on high-growth markets such as biologics.

With US sales forecast to contract, pharmaceutical companies have turned to cost cutting and restructuring their US operations, while expanding in the high growth emerging markets. In fact, branded sales in the rest of world markets are forecast to represent 30.0% of sales in the Branded PharmaVitae Universe in 2016.

The pharmaceutical industry is shifting its RandD focus toward developing novel, high value, and often biologic therapies for the treatment of more niche indications. Reflecting this, infectious diseases and oncology are forecast to experience strong growth with additional sales of $10bn and $26bn by 2016, respectively.

Reasons to Get this Report:

- Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2016
- Quantify the size and growth of the pharmaceutical market
- Assess drivers and resistors of the prescription pharmaceutical market

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- The Pharmaceutical Market: USA
- Prescription Pharmaceutical Market Sales Overview - Analysis of prescription pharmaceutical sales across 12 major markets
- The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities
- Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
- Pharmaceutical Company Outlook to 2014
- Japan Pharmaceutical Market Overview Regulatory reforms will stimulate generics uptake
- The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets
- Multi-therapy Drugs: Opportunities for Generics & Biosimilars
- UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth
- Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape